Lexicon Pharmaceuticals (LXRX) Q4 2025 earnings summary

Executive summary

• Advanced late-stage pipeline in cardiometabolic disease, chronic pain, and obesity, including sotagliflozin for HCM and T1D, pilavapadin for neuropathic pain, and LX9851 for obesity, with global expansion and productive FDA meetings.

• Achieved key milestones: over 50% enrollment in SONATA-HCM Phase III, NDA resubmission for Zynquista (T1D) planned for 2026, pilavapadin Phase III readiness, and global regulatory progress.

• Strengthened financial position with over $100 million in new capital from equity raises and milestone payments.

Financial highlights

• Q4 2025 revenues: $5.5 million; full year 2025 revenues: $49.8 million, mainly from Novo Nordisk licensing ($45 million upfront, $4.3 million Q4) and INPEFA sales ($4.6 million full year, $1.1 million Q4).

• Q4 2025 net loss: $15.5 million ($0.04/share), improved from $33.8 million in Q4 2024; full year 2025 net loss: $50.3 million ($0.14/share), down from $200.4 million in 2024.

• Operating expenses reduced by $39 million in Q4 2025 vs. Q4 2024; full year operating expenses down $129.5 million year-over-year.

• Ended 2025 with $125.2 million in cash and investments; post-year-end, cash position increased by $100 million from equity and milestone payments.

• Reduced total debt by $46.3 million in 2025, primarily using Novo Nordisk proceeds.

Outlook and guidance

• 2026 operating expenses expected at $100–$110 million; R&D $63–$68 million (excluding pilavapadin Phase III), SG&A $37–$42 million.

• SONATA-HCM Phase III enrollment to complete by mid-2026, with topline data in Q1 2027.

• NDA resubmission for Zynquista (T1D) planned for 2026, with potential approval by year-end.

• Ongoing partnership discussions for pilavapadin Phase III; not planning to self-fund pivotal trial.